Cardiac Arrhythmias.

Slides:



Advertisements
Similar presentations
By Dr.Ahmed Mostafa Assist. Prof. of anesthesia & I.C.U.
Advertisements

Cardiac action potential
TACHYCARDIAS Dr Kirsten Cohen
ARRHYTHMIAS TACHYCARDIA>100/min BRADYCARDIA
Or Doing Drugs for Your Heartbeat
Aims Introduction to the heart.
Na+ channel blocker: Na+ channel block depends on: HR
Mechanisms of cardiac arrhythmias
ANTIARRHYTHMIC DRUGS Arrhythmia or dysrhythmia means an abnormal or irregular heart beat Arrhythmias may originate in the atria, SA node or AV node, whereby.
Pharmacology I Drugs Used to Treat Arrhythmias. Arrhythmias Needing Treatment: Atrial Fibrillation/Flutter (AF) Supraventricular Tachycardia (SVT) Ventricular.
Electrical Activity of the Heart
Mechanism of Arrhythmia Fellow School Lecture Series Mahmoud Houmsse, MD. July 11 th, 2014.
Drugs used to treat cardiac arrhythmias
Arrhythmia Arrhythmias are abnormal beats of the heart.
Anti-arrhythmic drugs
Anti arrhythmic Drugs Marwa A. Khairy , MD.
Calcium Antagonists Tatyana Voyno-Yasenetskaya
Section 2 Electrophysiology of the Heart
ANTIARRHYTHMIC DRUGS Department of Pharmacology and Toxicology
© Assoc. Prof. Ivan Lambev
Section 3, Lecture 4 Antiarrhytmic drugs cont…
Copyright © The McGraw-Hill Companies, Inc. Permission required for reproduction or display. 1 CHAPTER 23 Antiarrhythmic Drugs.
Arrhythmias and Antiarrhythmic Drugs
S Allen 2003 Understanding and Management Of ECG’s.
CARDIOVASCULAR SYSTEM PHYSIOLOGY. Pulmonary circulation: Path of blood from right ventricle through the lungs and back to the heart. Systemic circulation:
CARDIAC ARRHYTHMIA Catherine Seger Medicinal Chemistry.
Antiarrhythmic Agents. BACKGROUND Inside cell: K + ; Outside cell: Na +, Ca + +, Cl - Action potential (AP) and Phase 0-4 phase0---reactivity---conduction---
Chapter Goals After studying this chapter, students should be able to describe the general functions of the major components of the heart. 2. describe.
Guyton 2011 pages Berne 2008 pages
Cardiac electrical activity
Abnormal Sinus Rhythms
Lecture Objectives Describe sinus arrhythmias Describe the main pathophysiological causes of cardiac arrhythmias Explain the mechanism of cardiac block.
Good Morning 20 August Anesthetic Considerations in Patients With Cardiac Arrhythmias 麻醉科 林子富.
Calcium Channel Blockers and Digitalis. Dig Ca Channel Blockers.
Antiarrhythmic Drugs Dr. Tom Murray Department of Pharmacology.
Section 3 Lecture 3 Antiarrhythmic Drugs Heart beats (HB) originate from AV node Normal 70 beats/min at rest Arrhythmia (dysrhythmia): Abnormal.
Electrical Activity of Heart & ECG
Cardiac conducting system Anatomy and Physiology QUIZ.
23 Antiarrhythmic Drugs.
MECHANISMS OF CARDIAC ARRHYTHMIAS. DR AMNA TAHIR PHYSIOLOGY DEPARTMENT. KEMU.
Arrhythmias. Cardiac dysrhythmia Cardiac dysrhythmia (arrhytmia) Abnormal electrical activity in the heart.
ANTI-ARRHYTHMIC DRUGS
Electrocardiography – Abnormalities (Arrhythmias) 7
ACTION POTENTIAL CHARACTERISTICS OF SPECIALIZED CELLS
Dr. Mona Soliman, MBBS, MSc, PhD Associate Professor Department of Physiology Chair of Cardiovascular Block College of Medicine King Saud University.
Cardiac Arrhythmia.
Pharmacology 4 Dr. Khalil Makki. Antiarrhythmic Drugs.
Arrhythmia Arrhythmias are abnormal beats of the heart.
Electrophysiology of the Heart J.M. Cairo, Ph.D. Telephone:
Antiarrhythmic Drugs.
Copyright © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 33 Disorders of Cardiac Conduction and Rhythm.
ARRHYTHMIAS Jamil Mayet. Arrhythmias - learning objectives –Mechanisms of action of antiarrhythmic drugs –Diagnosis To differentiate the different types.
Cardiovascular Cardiovascular pharmacology pharmacology.
Cardiac Arrhythmias An Introduction: Dr.S.Nandakumar.
Dr. Aisha Riaz Department of Physiology. parts of the heart normally beat in orderly sequence contraction of the atria (atrial systole) is followed by.
Copyright © 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 25 Disorders of Cardiac Conduction and Rhythm.
Tachykardie / bradykardie
Electrical Properties of the Heart
Atrial and Ventricular Arrhythmias
Chapter 4 Atrial Rhythms.
Antiarrhythmic Drugs 7/28/2018.
©2012 Lippincott Williams & Wilkins. All rights reserved.
Molecular and Cellular Mechanisms of Cardiac Arrhythmias
CVS Impulse generation
Antiarrhythmic drugs [,æntiə'riðmik] 抗心律失常药
Natural Excitation of the Heart
Chapter 30 Antiarrhythmic Drugs
Antiarrhythmic Drugs Types of Cardiac Arrhythmias:
Arrhythmias Simple-dysfunction cause abnormalities in impulse formation and conduction in the myocardium. However, in clinic it present as a complex family.
Drugs used in the treatment of arrhythmia I
Presentation transcript:

Cardiac Arrhythmias

Types of cardiac arrhythmias: Bradyarrhythmias Tachyarrhythmias Bradyarrhythmias: treat with atropine, pacing Tachyarrhythmias can occur due to: Enhanced automaticity Afterdepolarization and triggered activity Re-entry

Tachyarrhythmias: Enhanced automaticity: In tissues undergoing spontaneous depolarization -stimulation, hypokalemia, mechanical stretch of cardiac muscle Automatic behaviour in tissues that normally lack spontaneous pacemaker activity e.g. ventricular ischaemia depolarizes ventricular cells and can cause abnormal rhythm Afterdepolarization: EAD: when APD is markedly prolonged Occur in phase 3 May be due to inwards Na+ or Ca2+ current Excessive prolongation of APD- torsades de pointes syndrome

EAD DAD

Torsades de pointes: polymorphic ventricular tachycardia along with prolonged QT interval DAD: precipitating conditions are intracellular or sarcoplasmic Ca2+ overload, adrenergic stress, digitalis intoxication, heart failure If afterdepolarizations reach a threshold, an AP is genererated which is called ‘triggered beat’ DAD occur when the HR is fast, EAD occur when the HR is slow Re-entry: when a cardiac impulse travels in a path such as to return to and reactivate its original site and self perpetuate rapid reactivation independent of normal sinus node conduction

Requirements for re-entry rhythm: slowing or conduction failure due to either an anatomic or functional barrier Anatomic barrier- Wolff-Parkinson-White syndrome Functional barrier- ischaemia, differences in refractoriness Presence of an anatomically defined circuit Heterogenecity in refractoriness among regions in the circuit Slow conduction in one part of the circuit

What are channels? – they are macromolecular complexes consisting of a pore forming  subunit,  subunits and accessory proteins They are: Transmembrane proteins Consist of a voltage sensitive domain A selectivity filter A conducting pore and, An inactivating particle In response to changes in membrane voltage, the channel changes conformation so as to allow or prevent the flow of ions through it along their concentration gradient

K+ (Transient) K+ (delayed rectifier) Ca2+ Ca2+ Na+ Na+ Na+K+ATPase K+

K+ channel blocker -blocker, CCB Na+ channel blocker

Ca2+ channel blocker & -blocker

How can drugs slow the cardiac rhythm? Decreasing phase 4 slope Increase in threshold potential for excitation Increase in maximum diastolic potential Increase in APD Fast response tissues Slow response tissues

Na+ channel blocker: Na+ channel block depends on: HR Membrane potential Drug specific physiochemical characteristic-  recovery Blockade of Na+ channels results in: Threshold for excitability is increased (more current) Increase in pacing and defibrillation threshold Decrease conduction velocity in fast response tissues Increase QRS interval Some drugs tend to prolong PR interval- flecainide (possibly Ca2+ channel blockade)

Some sodium channel blockers shorten the PR interval (quinidine; vagolytic effect) APD unaffected or shortened Increase in threshold for excitation also decreases automaticity Can also inhibit DAD/EAD Delays conduction so can block re-entry In some cases, it can exacerbate re-entry by delaying conduction Shift voltage dependence of recovery of sodium channels from inactivated state to more negative potentials and so increases refractoriness Net effect- whether it will suppress or exacerbate re-entry arrhythmia depends on its effect on both factors- conduction velocity and refractoriness

Most Na+ channel blockers bind to either open or inactivated state and have very little affinity for channels in closed state, drug binds to channels during systole & dissociates during diastole ADRs: Decrease in conduction rate in atrial flutter- slows rate of flutter and increases HR due to decrease in AV blockade Especially common with quinidine due to its vagolytic property; also seen with flecainide and propafenone Cases of ventricular tachycardia due to re-entrant rhythm following MI may worsen due to slowing of conduction rate Slowing of conduction allows the re-entrant rhythm to persist within the circuit so that complicated arrhythmias can occur Several Na+ channel blockers have been reported to exacerbate neuromuscular paralysis by d-tubocurarine

K+ Channel blockers: Prolong APD (QT interval) and reduces automaticity Increase in APD also increases refractoriness Effective in treating re-entrant arrhythmias Reduce energy requirement for defibrillation Inhibit ventricular arrhythmias in cases of myocardial ischemia Many K+ channel blockers also have  blocking activity also like sotalol Disproportionate prolongation of APD can result in torsaides de pointes, specially when basal HR is slow

CCBs: Major effect on nodal tissues Verapamil, diltiazem and bepridil cause slowing of HR, nifedipine and other dihydropyridines reflexly increase HR Decrease AV nodal conduction so PR interval increases AV nodal block occurs due to decremental conduction and increase in AV nodal refractoriness DAD leading to ventricular tachycardia respond to verapamil Verapamil and diltiazem are recommended for treatment of PSVT Bepridil increases APD in many tissues and can exert antiarrhythmic action in atria and ventricles but it use is associated with increased incidence of torsades de pointes- rarely used